Paul Tappenden BA (Nottingham Trent), MSc (Sheffield), PhD (Sheffield)

Tappenden1

HEDS, ScHARR
University of Sheffield
Regent Court, 30 Regent Street
Sheffield, S1 4DA

Office: 2013

Tel: (+44) (0)114 222 0855
Fax: (+44) (0)114 222 0749

E-mail: p.tappenden@sheffield.ac.uk

ORCiD: 0000-0001-6612-2332

Biography

I am a Reader in Health Economic Modelling within the Health Economics and Decision Science Section at ScHARR. I have over 12 years’ experience in designing, developing and critically appraising health economic models across a number of disease areas. Since joining ScHARR in 2000, I have been involved in a number of research studies for the National Institute for Health and Care Excellence (NICE), including modelling the cost-effectiveness of beta-interferon and glatiramer-acetate in the management of multiple sclerosis, modelling the cost-effectiveness of influenza prophylaxis and modelling the cost-effectiveness of technologies for the prevention, detection, treatment and follow-up of colorectal cancer. I have also undertaken modelling assessments for the NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC), the Advisory Group for National Specialised Services (AGNSS), the Department of Health and NHS Cancer Screening Programmes, including an options appraisal of colorectal cancer screening programmes. In 2011, I completed a fellowship funded by the NIHR evaluating the role and value of developing health economic models of whole disease and treatment pathways (Whole Disease Modelling).

Research interests

My main research interests are:

• Health economic modelling
• Economic analyses of therapies for multiple sclerosis
• Economic analyses of cancer therapies
• Whole disease modelling

Teaching interests

I currently teach on the MSc in Health Economics and Decision Science, the MSc in International Health Technology Assessment, Pricing and Reimbursement and the MSc(Res) in Translational Oncology.

Professional activities

I am Deputy Technical Director for the ScHARR Technology Assessment Group and a member of the NICE Decision Support Unit. I am a member of NICE Technology Appraisal Committee C.

Current projects

Amongst others, I am currently working on the following projects:

• The clinical effectiveness and cost-effectiveness of FeNO testing for the diagnosis and management of asthma (NICE)
• Frequency of follow-up for patients with intermediate grade adenomas (NIHR)
• The clinical effectiveness and cost-effectiveness of eculizumab for the treatment of atypical haemolytic uraemic syndrome (NICE)
• The clinical effectiveness and cost-effectiveness of infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (NICE)

Section

Paul Tappenden is based in Health Economics and Decision Science (HEDS).

Health Economics and Decision Science

Extended List of Publications

Journal articles